Skip to main content
AmigoFish

Argobio: the venture model building Europe’s next biotech champions

From Beyond Biotech - the podcast from Labiotech · · 42 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Our guest today is Thierry Laugel, Managing Partner of Kurma & Chairman of Argobio. With a PharmD, PhD in pharmacology, and an INSEAD MBA, Thierry has spent more than two decades bridging cutting-edge science and commercial success—first in pharma R&D, then as co-founder of Kurma Partners, and now leading Argobio’s unique venture-builder model.

Since raising €50 million in 2021, Argobio has co-founded and accelerated several companies from top European academic labs. Three of them—Enodia, Laigo Bio, and Elkedonia—have already closed seed rounds totaling more than €43 million, advancing novel platforms in targeted protein degradation, precision membrane protein degraders, and non-hallucinogenic neuroplasticity enhancers for depression.

Thierry shares how Argobio reduces execution risk, embeds operational expertise, and turns promising science into investable companies that can compete worldwide.

- 04:02 Blending pharmacology expertise with business

- 07:50 Vision behind starting Kurma Partners

- 12:53 Launching Argobio to address gaps in European biotech

- 17:40 What makes the Argobio operational venture builder model unique

- 25:02 Criteria for selecting academic scientific breakthroughs

- 27:34 Changing dynamics of commercializing European research

- 35:30 Europe vs US biotech investment climates

- 37:47 Role of venture studios in Europe’s biotech future

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast)

Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast)

To dive deeper into the topic:

- M Ventures: pharma CVC and biotech innovation in 2026 (https://podcast.labiotech.eu/1995493/episodes/18453766-m-ventures-pharma-cvc-and-biotech-innovation-in-2026)

- Inside Flagship Pioneering's strategy: How this VC turns ideas into biotech giants (https://podcast.labiotech.eu/1995493/episodes/17108243-inside-flagship-pioneering-s-strategy-how-this-vc-turns-ideas-into-biotech-giants)

- Venture capital co-creation: The next big thing in biotech investment? (https://podcast.labiotech.eu/1995493/episodes/16441913-venture-capital-co-creation-the-next-big-thing-in-biotech-investment)

Back to Beyond Biotech - the podcast from Labiotech · Report a problem